Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2026

The paroxysmal nocturnal hemoglobinuria (pnh) market size has grown strongly in recent years. It will grow from $4.67 billion in 2025 to $5.09 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited availability of effective targeted therapies, delayed diagnosis due to rarity of the disease, reliance on supportive care and transfusions, high mortality associated with untreated pnh, lack of awareness among general healthcare providers.

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to development of next-generation complement inhibitors, increasing diagnosis rates through advanced testing, growing focus on orphan disease treatment, rising access to specialized hematology centers, expansion of reimbursement coverage for rare disease therapies. Major trends in the forecast period include rising adoption of complement inhibitor therapies, increasing use of flow cytometry for accurate diagnosis, growth of long-acting monoclonal antibody treatments, expansion of specialized rare hematology care programs, improved management of thrombosis and hemolysis complications.

The increasing number of blood and bone marrow-related disorders is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are conditions that affect the composition, function, or production of blood and its components, while bone marrow disorders arise when the marrow produces insufficient or defective red cells, white cells, or platelets. PNH is closely associated with both blood and bone marrow disorders because it disrupts blood cell production, immune regulation, and the bone marrow microenvironment. It is a rare hematologic condition linked to bone marrow failure syndromes and occurs due to a genetic defect that impairs the normal functioning of red blood cells and platelets. For example, according to Blood Cancer United, a UK-based nonprofit advocacy organization supporting individuals with blood cancers, approximately 192,070 people in the United States are projected to be diagnosed with leukemia, lymphoma, or myeloma in 2025. Therefore, the rising prevalence of blood and bone marrow disorders is contributing to the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are increasingly concentrating on the development of novel and advanced therapies, such as injectable C5 inhibitors, to maintain their competitive position. Injectable C5 inhibitors are monoclonal antibodies that block the complement component C5, thereby reducing complement-mediated inflammation and tissue damage in autoimmune conditions such as PNH. For instance, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China’s National Medical Products Administration (NMPA) for a treatment for paroxysmal nocturnal hemoglobinuria. This approval made China the first country to authorize PIASKY ahead of other major markets, enabling the drug to enter National Reimbursement Drug List (NRDL) negotiations within the same year. PNH is classified as a rare disease and is estimated to affect approximately 12,740 individuals in China, highlighting notable market potential.

In March 2024, Gilead Sciences, Inc., a US-based biopharmaceutical company specializing in therapies for life-threatening diseases, acquired Cymabay Therapeutics, Inc. for $4.3 billion. Through this acquisition, Gilead aimed to strengthen its liver disease treatment portfolio by adding seladelpar, a therapy under development for primary biliary cholangitis that addresses significant unmet medical needs. Cymabay Therapeutics, Inc. is a US-based pharmaceutical company developing seladelpar as a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH).

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc, Novartis AG, Thermo Fisher Scientific Inc, GE Healthcare, Grifols S.A, Genentech Inc, Bioverativ Inc, BioCryst Pharmaceuticals, Hansa Biopharma AB, Apellis Pharmaceuticals Inc, Akari Therapeutics Plc, RA Pharmaceuticals Inc, C5 Therapeutics Inc, Omeros Corporation, Amyndas Pharmaceuticals SA, CANbridge Pharmaceuticals, NovelMed Therapeutics Inc, Annexon Inc, Dianthus Therapeutics, DynamiCure Biotechnology, Kira Pharmaceuticals Ltd, Kyowa Kirin Co Ltd, Swedish Orphan Biovitrum AB, Arrowhead Pharmaceuticals, ReAlta Life Sciences, Q32 Bio, ISU Abxis.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2025. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paroxysmal nocturnal hemoglobinuria (pnh) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the paroxysmal nocturnal hemoglobinuria market by increasing costs for imported biologic drugs, diagnostic reagents, and specialized laboratory equipment used in diagnosis and treatment. Hospitals and clinics in north america, europe, and asia-pacific are most affected due to dependence on global pharmaceutical and diagnostics supply chains. These tariffs may increase treatment costs and slow access to advanced therapies. However, they also encourage domestic manufacturing of biologics, regional sourcing of diagnostics, and supply chain diversification, supporting long-term market resilience.

The paroxysmal nocturnal hemoglobinuria (pnh) market research report is one of a series of new reports that provides paroxysmal nocturnal hemoglobinuria (pnh) market statistics, including paroxysmal nocturnal hemoglobinuria (pnh) industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria (pnh) market share, detailed paroxysmal nocturnal hemoglobinuria (pnh) market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (pnh) industry. This paroxysmal nocturnal hemoglobinuria (pnh) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder characterized by the abnormal destruction of red blood cells due to the absence of specific protective proteins on their surface. It is a serious condition that can result in reduced blood cell production and increased risk of life-threatening complications. PNH presents with a broad range of symptoms, including fatigue, shortness of breath, abdominal pain, and thrombosis, which involves the formation of blood clots.

The main treatment approaches for paroxysmal nocturnal hemoglobinuria (PNH) include medications, bone marrow transplantation, blood transfusions, immunosuppressive therapy, and other options. Medications are substances specifically developed to diagnose, treat, prevent, or relieve diseases or symptoms in humans and animals. Diagnostic methods used in PNH include flow cytometry, high-resolution mass spectrometry, and other techniques, which are utilized by various end users such as hospitals, clinics, and others.

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.